Meta Pixel

News and Announcements

Bricklet Series A Opens After Almost $9m Sales In First Quater

  • Published March 20, 2020 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

BRICKLET, Australia’s only property fragmentation platform, has officially opened its Series A Funding Round as it looks to capitalise on a successful first quarter.

BRICKLET sold almost $9 million worth of bricklets in its first quarter of 2020, including 259 bricklets in development project Roxy Muse – an over 55s seven-unit apartment block development set to be complete by December 2021.

BRICKLET is aiming to raise $3 million in this latest funding round. Mirvac and Stockland are currently leading the round, with over $1 million already committed. BRICKLET is looking to raise funds to take advantage of an untapped $375bn fragmented property market.

BRICKLET’s current markets are SMSFs and the sophisticated investment community, a market worth over $75 billion. BRICKLET’s next phase is addressing the $300 billion consumer investment market, following the approval of its retail investment licence.

BRICKLET launched in December 2019, to help more people access the property market and the investment opportunities that come with it. It achieves this by fragmenting the Torrens Title into individual, affordable bricklets (fragments). Bricklet owners are a registered owner of that fragment on title and receive all the benefits that come with owning an investment property – such as rental and capital yields.

BRICKLET’s Deal Room for Series A is now open on CRIISP. To find out more information, click here.

Register Interest

About Bricklet

Fragmentation is the new way to invest in property. A property can be split into ‘bricklets’ and then each bricklet is sold individually. Giving investors the opportunity to own a proportion of the property, at a fraction of the cost.

BRICKLET is the world’s only property exchange, providing a market for tradable fragments of real estate. It provides a full suite of services including listings, trading, clearing, settlement, technical and information services, and other post-trade services.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now